Remove Competition Remove Manufacturing Remove Pharmaceutical manufacturing
article thumbnail

Elevating pharmaceutical manufacturing processes with real-time insights

European Pharmaceutical Review

To address these issues, companies should adopt more advanced production strategies such as continuous flow chemistry, as they can shorten manufacturing processes, increase productivity and throughput. The result is efficient, cost-effective and high-quality (bio)pharmaceutical production.

article thumbnail

Unified vision essential in UK advanced manufacturing

European Pharmaceutical Review

The Association of the British Pharmaceutical Industry (ABPI) has drawn attention to a new report , which has emphasised the importance of UK advanced manufacturing requiring a long-term strategy to ensure its continued success. Article: Are we globally prepared for the next pandemic?

article thumbnail

Why prefilled vial capacity is key to a competitive edge in pharmaceuticals manufacturing 

Pharmaceutical Technology

With many biopharma companies outsourcing for manufacturing support, how can your organisation outpace the competition?

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. Since 2010, the UK has fallen from 4th to 98th place in overall trade balance in pharmaceuticals, due to fierce global competition, according to the MMIP.

article thumbnail

Is the pharmaceutical sector realising its potential for sustainable manufacturing?

European Pharmaceutical Review

The pharmaceutical industry is becoming increasingly conscious of emissions and the importance of sustainable manufacturing. Globally, the pharmaceutical sector emitted around 52 megatonnes of CO 2 in 2015, the most recent period for which detailed numbers are available.

article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

The US Food and Drug Administration (FDA) believes the adulteration of heparin was an economically motivated act—a clear breach of the US pharmaceutical supply chain. Ironically, in later times, the intense competition for out-of-patent drugs has subsided, which has led to spiraling rises in generic drug prices and shortages.

article thumbnail

Embracing automation in sterile manufacturing

European Pharmaceutical Review

In the interview, conducted at CPHI Barcelona, Krishna Venkatesh, Global Head, Sterile Manufacturing Operations at Dr Reddy’s Laboratories explores industry’s growing focus on achieving end-to-end connectivity, as well as the potential of automation and track and trace solutions. KV : We have seen two specific elements.